Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.

For the SIADH/cancer subgroup, subjects on tolvaptan exhibited a highly significant improvement in this parameter ( P < 0.0001) relative to placebo to day 4 (5.0 vs. −0.3 mEq/mL) and to day 30 (6.9 vs. 1.0 mEq/L) (Fig. 2 ).

also in 132,142 other papers